PSMA SPECT-CT in Prostate cancer

Radiolabelled 68Ga/18F prostate-specific membrane antigen (PSMA) PET-CT is increasingly used in imaging prostate cancer. However, PSMA SPECT-CT imaging might be a useful alternative in nuclear medicine departments where access to PSMA-PET-CT imaging is limited. The clinical uses of SPECT tracers in the management of PCa are increasingly explored and the evidence is evolving in several clinical scenarios.

Objectives

1. To review potential role of 99mTc-PSMA SPECT-CT imaging in prostate cancer

2. Review current evidence and clinical roles in both diagnostic and therapeutic setting

Intended Audience

Nuclear Medicine and oncology professionals including physicians, Surgeons, Nuclear Medicine Technologists, radiographers, nurses, physicists, healthcare professionals who specialise in Nuclear Medicine, Oncology and treating patients with radionuclide therapies.

Introduction: 13:00-13:05

99mTc-PSMA SPECT-CT: UK experience: 13:05-13:25 - Dr Sabina Dizdarevic

1. Rationale for starting 99mTcPSMA service
2. How the service is funded
3. Replacing other CT and bone scans
4. Patient Selection
5. Indication, PSA levels etc.
6. Case studies and influence on management

99mTc-PSMA SPECT-CT: Current evidence: 13:25-13:45 - Simona Malaspina

1. Review of literature

1. Ongoing trials

1. How 99mTcPSMA can be useful in-patient selection for therapies / therapy response
2. Replacing bone scan in primary staging?

99mTc-PSMA: Radiopharmacists perspective: 14:05-14:15 - Christopher Barnett

1. Brief explanation of labelling procedure
2. Tips when labelling MIP5060 kit
3. How to production incorporate into current workflow

Panel Discussion: 14:15-14:45